Dr. Tomlinson, said, "Older patients with active, relapsed or refractory AML are an underserved patient population. These patients, particularly those with high blast counts as seen in the SIERRA trial, are not typically considered candidates for transplant, which is a potentially curative treatment for AML, and have a poor prognosis with other therapeutic options. Iomab-B has uniquely demonstrated an ability to effectively condition these patients for transplant with robust engraftment. We hypothesized that this successful engraftment is due to the myeloablation and anti-leukemic effect of Iomab-B, since these patients had a median of 30% bone marrow blasts prior to transplant. Therefore, we are highly encouraged to observe that Iomab-B as a single agent has a significant anti-leukemic effect and rapidly reduces peripheral blasts
|
